ArticleOncotarget2017
Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 108 citations in OpenAlex.
- Combined RAS and SMAD4 Mutations and Microsatellite Instability Predict Outcomes in Colorectal Lung Metastases Treated with Image-Guided Thermal Ablation.Annals of surgical oncology · 2026Article
- Histotripsy for liver tumours: a systematic review and meta-analysis of current clinical evidence.EClinicalMedicine · 2026Article
- Interventional Oncology for Colorectal Liver Metastases: From Local Cure to Salvage Therapy.Biomedicines · 2025Review
- The complex journey of targeting RAS in oncology.BMC cancer · 2025Review
- The Impact of KRAS Status on Long-Term Outcomes After Thermal Ablation and Hepatic Resection for Liver-Only Colorectal Metastases: A New Clue for Tailoring Surgical Strategy on Tumor Biology?World journal of surgery · 2025Article
- Quantitative Ablation Confirmation Methods in Percutaneous Thermal Ablation of Malignant Liver Tumors: Technical Insights, Clinical Evidence, and Future Outlook.Radiology. Imaging cancer · 2025Review
- High-Frequency Mutations in TP53, AXIN1, CTNNB1, and KRAS, and Polymorphisms in JAK1 Genes Among Mongolian HCC Patients.Cancer reports (Hoboken, N.J.) · 2025Article
- Evaluation of the Ki-67 labeling index on immediate pre-ablation biopsies as a predictive biomarker of local recurrence of colorectal cancer liver metastases.Cytotechnology · 2025Article
- Technical aspects, methodological challenges, and factors predicting outcomes of percutaneous ablation for colorectal liver metastases.Polish journal of radiology · 2025Review
- Imaging Considerations before and after Liver-Directed Locoregional Treatments for Metastatic Colorectal Cancer.Diagnostics (Basel, Switzerland) · 2024Review
- Molecular profiling and patient selection for the multimodal approaches for patients with resectable colorectal liver metastases.Hepatobiliary surgery and nutrition · 2024Review
- Three-Dimensional Margin as a Predictor of Local Tumor Progression after Microwave Ablation: Intraprocedural versus 4-8-Week Postablation Assessment.Journal of vascular and interventional radiology : JVIR · 2024Article
- Optimizing Treatment Strategy for Oligometastases/Oligo-Recurrence of Colorectal Cancer.Cancers · 2023Review
- Review
- PET/CT in assessment of colorectal liver metastases: a comprehensive review with emphasis onClinical & experimental metastasis · 2023Review
- Fibroblast growth factors induce hepatic tumorigenesis post radiofrequency ablation.Scientific reports · 2023Article
- Gradient-based Volumetric PET Parameters on Immediate Pre-ablation FDG-PET Predict Local Tumor Progression in Patients with Colorectal Liver Metastasis Treated by Microwave Ablation.Cardiovascular and interventional radiology · 2023Article
- Ablative Margins of Colorectal Liver Metastases Using Deformable CT Image Registration and Autosegmentation.Radiology · 2023Article
- The Impact of KRAS Status on the Required Surgical Margin Width for Colorectal Liver Metastasis Resection.Journal of clinical medicine · 2023Article
- Predictive Factors of Local Recurrence after Colorectal Cancer Liver Metastases Thermal Ablation.Journal of imaging · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundKras mutation has been associated with shorter overall survival and time to disease recurrence after resection of colorectal liver metastases (CLM). This study evaluated the prognostic value of Kras mutation in patients with CLM treated by percutaneous radiofrequency ablation (RFA).
methodsThis is an IRB waived retrospective analysis of the impact of KRAS mutation status on oncologic outcomes after CLM RFA. The endpoints were overall survival (OS), local tumor progression (LTP) rates, and incidence of new liver, lung, and peritoneal metastases. Survival times were calculated using Kaplan-Meier methodology from the time of RFA.
resultsThe study enrolled 97 patients. Kras exon 2 mutation was detected in 39% (38/97) of patients. On univariate analysis, Kras mutation (P=0.016) (HR: 1.8; 95% CI: 1.1 - 2.9) was a significant predictor of OS and retained significance on multivariate analysis. Kras mutation was a significant predictor of new liver metastases (P=0.037) (SHR: 2.0; CI: 1.0-3.7) and peritoneal metastases (P=0.015) (sHR: 3.0; 95% CI: 1.2-7.2) on multivariate analysis. Kras mutation was a significant predictor of LTP after RFA of CLM ablated with margins of 1-5 mm (P=0.018) (SHR: 3.0; 95% CI: 1.2-7.7) with an LTP rate of 80% (12/15) versus 41% (11/27) for wild type.
conclusionKras mutation is a significant predictor of overall survival, new liver, and peritoneal metastases after RFA of CLM. A minimal radiographic ablation margin ≥ 6 mm is essential for local tumor control especially for mutant CLM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.